Enforcement Report - Week of December 27, 2023
The years-long saga of the Competition and Markets Authority (CMA)’s investigation into Pfizer and Flynn Pharma has come to a head with a combined 70 million pound ($83.61 million) fine. The U.K. antitrust authorities claim the companies exploited a loophole to massively hike prices.
Gannex, a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces positive topline results from the U.S. Phase I trial of drug-drug interactions in healthy subjects and pharmacokinetics (PK) in patients with non-alcoholic fatty liver disease (NAFLD) for ASC41 oral tablets, a liver-targeted prodrug. ASC41 is mainly metabolized by CYP3A4 to form an active metabolite ASC41-A, a selective thyroid hormone receptor beta (THR?) agonist.
Enforcement Report - Week of March 4, 2020
Taro Pharmaceuticals U.S.A. Issues Voluntary Nationwide Recall of Phenytoin Oral Suspension
It says its phenytoin sodium capsules are already cheaper than alternative drugs available in the UK and have been sold at a price negotiated with the Department of Health for the past nine years.
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today presented positive results from the LATTE-2 study at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. Headline results were announced in November 2015.
Anvisa Suspends the Import of All Pharmaceutical Raw Materials from Sinbiotik SA, Mexico